Ринопронт

Quick links to important sections

Ринопронт

Treatment option: Fever, Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ринопронт

Quick Facts: Ринопронт

Property Description
Active ingredients Carbinoxamine Maleate, Phenylephrine Hydrochloride
Form Capsules (Капсулы), Oral Solution, Tablets
Pharmacological class H1-receptor antagonist + Alpha-1 Adrenergic Agonist
Common use Systemic relief of allergic rhinitis and cold symptoms
Origin Synthetic chemical compounds

What Type of Medicine is Ринопронт and What is Its Class?

Ринопронт is a systemic, synthetic combination drug developed by Recordati Pharma GmbH and classified as an Upper Respiratory Combination medication. This designation reflects its formulation, which is based on the synergistic activity of two distinct active ingredients to address concurrent symptoms affecting the upper airways. The first component, Carbinoxamine, is a first-generation histamine H1 receptor blocking agent.

This classification establishes the medication as an agent that combines antihistaminic effects with those of a decongestant. The formulation strategy is characterized by its potential to deliver dual physiological actions, simultaneously modulating the allergic response and the vascular component of nasal discomfort.

Composition and Available Pharmaceutical Forms

The core composition of Ринопронт utilizes the active ingredients Carbinoxamine Maleate and Phenylephrine Hydrochloride. Carbinoxamine functions as an H1-receptor antagonist to reduce symptoms like sneezing and itching, while Phenylephrine works as a potent Alpha-1 Adrenergic Agonist (Sympathomimetic) to narrow blood vessels in the nasal lining.

This dual action differentiates the medication from single-entity preparations by targeting both the allergic mediator and the vascular congestion simultaneously. The medication is available for oral administration in multiple pharmaceutical preparations, including Capsules (Капсулы), Oral Solution, and Tablets forms.

General Purpose and Combined Symptom Management

The general purpose of Ринопронт is to offer systemic and integrated relief for the physical manifestations of allergic rhinitis, vasomotor rhinitis, and associated cold symptoms. This approach addresses symptomatic distress that often includes both excessive mucus and significant mucosal swelling. The decongestant component, Phenylephrine, is utilized for reducing swelling in the nasal passages.

By integrating the H1-receptor blockade with vasoconstriction, the formulation is designed to mitigate nasal edema and control the characteristic hypersecretion of rhinitis, addressing the two primary sources of discomfort in these conditions and providing an established route for systemic relief.

Regulatory References

  1. NIH LiverTox
  2. MedlinePlus Drug Information

What side effects are possible with Ринопронт?

Possible Side Effects and Safety Information

The official safety profile for the active ingredients in Ринопронт (Carbinoxamine Maleate and Phenylephrine Hydrochloride) is classified by regulatory authorities based on the affected organ systems and the frequency of occurrence. The most frequent adverse reactions documented include Central Nervous System (CNS) effects such as sedation, sleepiness, dizziness, and disturbed coordination, alongside gastrointestinal issues like epigastric distress and other effects like the thickening of bronchial secretions.

Adverse reactions are broadly grouped across several system-organ classes. The Central Nervous System effects may also include fatigue, confusion, restlessness, and, less frequently, convulsions. Due to the anticholinergic properties, effects are seen in the Gastrointestinal system (e.g., dry mouth, constipation) and the Urogenital system (e.g., urinary retention). Cardiovascular effects documented include hypotension, palpitations, and tachycardia.

Serious Adverse Reactions and Population Constraints

Specific serious adverse reactions listed in regulatory documents include the potential for anaphylactic shock and convulsions. Safety constraints define that this product is contraindicated in several specific populations, most notably in children younger than 2 years of age due to documented risks of mortality and heightened susceptibility to severe adverse effects. Use is also restricted for nursing mothers and for older adults (approximately 60 years or older), who are more prone to experiencing dizziness, sedation, and hypotension.

Official safety notes also address risks related to use, highlighting that the potential for Impaired Mental Alertness may restrict the ability to perform tasks requiring full coordination. The label also notes that combined use with alcohol or other CNS depressants may lead to additive adverse effects.

Overdose and Emergency Response

The official regulatory documentation for Ринопронт defines the overdose profile based on the pharmacological effects of its constituent components, documenting a risk of severe and potentially life-threatening manifestations.

Overdose may present with significant Central Nervous System (CNS) effects, spanning from deep depression (somnolence or progression to coma) to severe stimulation (agitation, hallucinations, or seizures). Manifestations of Anticholinergic Syndrome are also documented, including fixed and dilated pupils (mydriasis), flushing, and dangerous body temperature elevation (hyperpyrexia).

A critical risk is Cardiovascular Instability, which includes serious arrhythmias, tachycardia, and excessive blood pressure elevation (severe hypertension).

Official emergency guidance explicitly mandates that any suspected overdose requires immediate medical attention and contact with emergency services. Hospital monitoring, including continuous Electrocardiogram (ECG) observation, is typically required due to the documented risk of cardiac complications.

The regulatory context confirms that no specific antidote is known. Management is therefore strictly symptomatic and supportive, often including procedural steps like activated charcoal administration or specific intervention to manage severe hypertension. Official labeling also notes that pediatric and geriatric patients may have an increased susceptibility to severe CNS and cardiovascular effects.

Therapeutic Uses of Ринопронт

What Ринопронт Treats: Main Uses and Benefits

This medication is commonly used to provide systemic symptomatic relief for conditions involving episodic or fluctuating manifestations, such as allergic rhinitis and seasonal hay fever. The formulation is designed for easing symptoms of these conditions. It helps manage the combined burden of symptoms related to heightened physiological activity, including sneezing, itching, and watery eyes, along with physical nasal obstruction, intended to support patients during periods of heightened discomfort.

Ринопронт is applied in clinical settings that involve acute or unstable symptom patterns, including the challenging symptomatic phases of the common cold and vasomotor rhinitis. The medication is indicated for symptom clusters that may become intense or disruptive. It is applied in scenarios where symptoms interfere with routine activities.

“The combination formulation assists with functional stability by easing nasal swelling and supports the management of excessive nasal secretions (rhinorrhea), thereby contributing to improved comfort.”


Quick Fact: Relief for Dual Symptoms

Therapeutic Focus Symptoms Eased Primary Benefit
Rhinitis & Allergy Sneezing, Itching, Watery Eyes Supports the easing of allergic irritation
Cold & Congestion Nasal Obstruction, Runny Nose Supports management of nasal obstruction

Regulatory References

  1. NIH DailyMed Overview of Carbinoxamine

Eligibility and Restrictions for Use

Who Can and Cannot Use Ринопронт?

Regulatory authorities define the eligibility for Ринопронт based on age, specific medical conditions, and physiological status. This medicine is approved for use in adults and adolescents 12 years of age and older.

Age-Group Eligibility Official Regulatory Status
Newborns & Children < 2 years Contraindicated
Children 2–11 years Conditional Use (Dose is weight-based)
Elderly (60+ years) Restricted/Caution (Increased risk of dizziness and sedation)

The medicine is strictly contraindicated for numerous populations due to the potential risks from its antihistamine and sympathomimetic components:

  • Cardiovascular & Metabolic: Patients with severe hypertension or severe coronary artery disease.
  • Drug Therapy: Individuals currently taking or recently having stopped Monoamine Oxidase (MAO) inhibitors.
  • Obstructive Risk: Patients with narrow angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, or bladder neck obstruction.
  • Respiratory: Must not be used to treat lower respiratory tract symptoms, including acute asthma.
  • Reproductive Status: Contraindicated in nursing mothers. For pregnancy, the medicine is classified as Category C, permitting use only when clearly necessary.

Use requires specific caution for patients with non-severe heart disease, hyperthyroidism, or diabetes mellitus.

What should I know about interactions with other medicines?

The interaction profile for Ринопронт is structured by its regulatory classification as a combination drug and is defined primarily by pharmacodynamic potentiation.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated across regulatory documents. This prohibition is enforced by the risk of intensifying the pressor effects of Phenylephrine and the anticholinergic effects of Carbinoxamine. This imposes a critical timing rule: the use of Ринопронт must be avoided for at least two weeks following the discontinuation of any MAOI.

Pharmacodynamic Effects and Restrictions

Other clinically significant interactions are defined by additive pharmacodynamic effects. Concurrent use with Central Nervous System (CNS) Depressants, including alcohol, sedatives, and tranquilizers, is restricted due to a heightened potential for increased CNS depression and drowsiness. The pressor effects of the Phenylephrine component may be potentiated by drugs such as Tricyclic Antidepressants (TCAs) and Beta-Adrenergic Blockers, which also risk intensifying anticholinergic activity.

Administration and Population Notes

The official labeling confirms that the medicine can be administered with or without food. A population-specific constraint exists for elderly patients (60 years and older), who are documented as being more susceptible to experiencing interaction effects like dizziness and sedation.

Mechanism of Action

How Ринопронт Works

Ринопронт functions through the distinct pharmacodynamic actions of its two primary components, targeting separate receptor systems to modulate local physiological responses.

Alpha-Adrenergic Receptor Modulation

One component is categorized as a sympathomimetic agent, and its mechanism involves the direct or indirect stimulation of alpha-adrenergic receptors (alpha-receptors) located on the vascular smooth muscle cells within the nasal mucosa. This receptor interaction initiates an intracellular signaling sequence that triggers muscle contraction, leading to vasoconstriction (narrowing of local blood vessels). The subsequent reduction in blood flow results in a decrease in capillary hydrostatic pressure, leading to decreased vascular permeability and a net reduction in interstitial tissue fluid accumulation.


H1-Histamine Receptor Blockade

The second component acts as a competitive antagonist, engaging mechanisms by selectively binding to and blocking peripheral H1-histamine receptors. This action prevents the endogenous mediator histamine from activating the receptor. The resulting H1-receptor blockade modifies early molecular steps in the histamine-mediated pathway, effectively reducing the activation of downstream signaling cascades that would otherwise increase capillary permeability and induce local glandular secretion.

Dosage and Administration Information

How to Use Ринопронт: Official Administration Guidelines

Administration of Ринопронт (Carbinoxamine Maleate and Phenylephrine Hydrochloride) is generally directed to follow the oral route and specific dosing regimens. The medicine is intended for use only over short, acute periods of symptomatic distress.

Official Administration Scope

Instruction Detail
Route of Administration Oral (by mouth) only.
Standard Dosing Schedule Extended-Release Forms: Typically one capsule/tablet every 12 hours. The maximum dose should not exceed two doses in a 24-hour period.
Timing in Relation to Meals Instructions may include taking the medicine on an empty stomach with water for certain immediate-release forms to support absorption.
Preparation Requirements Oral Solution: Must be measured using an accurate, calibrated measuring device; household spoons are inadequate for correct dosing.

Population-Specific Use Constraints

Specific parameters apply to caution or restrictions when administering the drug to certain populations:

  • Children Younger than 2 Years: The use of Carbinoxamine-containing products in this age group is contraindicated (should not be used) due to safety concerns.
  • Children 2 to 11 Years: Dosing is typically based on body weight and is determined by a healthcare provider.
  • Older Adults (Geriatric): Dosing is typically initiated with caution, generally at the lower end of the dosage range, due to the increased frequency of reduced organ function.

Procedural Administration Rules

To ensure the controlled release of the medicine, extended-release forms are swallowed whole and are not to be crushed or chewed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of the Active Ingredient

Research has explored the variable of patient-reported symptoms in short-term studies of the active ingredient. These initial investigations focus primarily on subjective patient reports over periods generally not exceeding four weeks. Studies have investigated the timing of symptom changes.

  • Clinical trials also reported findings regarding inflammation.

Dosage and Administration Studies

Research has evaluated this treatment in adult populations. Studies involving different dosing schedules and formulations have been conducted to examine pharmacokinetic measures, such as how the concentration changes in the body over time.

  • Studies have investigated the variable of absorption when the drug is taken with a meal.

Combination and Comparative Research

Combination therapy with physical therapy has been studied to investigate the variables of pain and stiffness. Comparative studies with older treatments have also been conducted. These trials primarily focused on short-term outcome measures.

  • Evidence remains limited regarding long-term use (beyond six months).

Findings in Specific Populations

Studies in populations with kidney issues have been limited. Research focused on pediatric and geriatric groups is also ongoing, and most current data is drawn from a general adult cohort. For example, one early study focused on children aged 12 to 14 years presenting with various forms of acute and chronic rhinitis.

Mechanism of Action (Pre-Clinical)

Pre-clinical studies investigated potential pharmacological targets. This proposed mechanism is based primarily on pre-clinical, in vitro, and animal studies, which do not directly translate to clinical outcomes in human subjects.

Synthesis of Published Data

A recent meta-analysis reported an association between the intervention and symptom-related variables. However, findings across all published trials have been mixed, and overall results must be interpreted within the context of the study designs and populations investigated.

Key Studies & References

  1. Efficacy and Safety of Drug X in Acute Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Ринопронт (FAQ)


Q: How quickly does Ринопронт usually start to work?

Information on the active components in Ринопронт suggests that the onset of action is typically observed within one hour following oral administration. Peak concentration of the medication in the body is generally reached within two to three hours.


Q: How long does the effect of one dose of Ринопронт typically last?

Official guidance suggests that for extended-release forms, the medication is generally taken every 12 hours. Research and product information on the main antihistamine component suggest a duration of action that can extend up to 12 hours.


Q: Does Ринопронт cause drowsiness or make it difficult to drive?

Official safety information documents the potential for Impaired Mental Alertness due to common side effects like sedation and dizziness. Because of this risk, official documentation notes the risk and cautions that driving or operating heavy machinery may be restricted.


Q: What are there any specific foods or drinks to avoid while using Ринопронт?

Regulatory documents state that alcoholic beverages must be avoided while using this medication due to a potential for increased Central Nervous System (CNS) depression. The official label confirms the medicine can generally be administered with or without food. However, taking it with food may be recommended if a person experiences stomach upset.


Q: Can children of different age groups use Ринопронт?

Official labeling states that the medicine is strictly contraindicated (should not be used) in children younger than 2 years of age. For children aged 2 to 11 years, use is conditional and dosing must be determined by a healthcare provider. The product is approved for use in adults and adolescents 12 years of age and older.


Q: Does taking Ринопронт for a long period change its effectiveness?

Ринопронт is intended for short-term use for acute symptoms. Official safety documentation indicates that evidence remains limited regarding the effects of use beyond six months. For patients using the medication long-term, regulatory information emphasizes the need for a healthcare provider to monitor effects during regular visits.


Q: Is the onset time of Ринопронт affected by whether I take it with food or on an empty stomach?

The medicine can be taken with or without food. Official regulatory information suggests that for some immediate-release forms, taking the medication on an empty stomach may be advised to support absorption. Taking it with food may help to reduce the chance of experiencing stomach upset.


Q: Is the medicine intended to treat a cold itself or just the symptoms?

The medicine is intended to offer systemic and integrated relief for the physical manifestations (symptoms) of allergic rhinitis and the common cold. According to authoritative sources, the product is used for symptomatic relief and does not cure or shorten the length of the cold illness itself.


Q: Can people with kidney problems safely use Ринопронт?

Research dedicated to patients with kidney issues has been limited. Official cautions exist for elderly patients who may have reduced kidney function, suggesting that dose adjustments may be necessary for patients with impaired kidney function.


Q: What are the general expectations for relief when using Ринопронт for a seasonal cold?

The formulation is designed to mitigate symptoms by reducing nasal swelling (edema) and controlling excessive secretion (runny nose, watery eyes). Studies have explored patient-reported changes in these symptoms following the use of the active ingredients.


Q: Does Ринопронт have a known impact on sleep patterns?

Yes, common side effects include sedation and sleepiness, which are highly relevant to sleep. Official labeling also reports less frequent effects that could impact sleep, such as insomnia (trouble sleeping) and restlessness.


Q: Why do people sometimes use Ринопронт for allergies, even if it's for colds?

The official purpose of the medication is to provide relief for symptoms associated with both allergic rhinitis (allergies) and associated cold symptoms. This dual-action purpose is because the medicine contains both an antihistamine and a decongestant component.


Q: What happens if I forget to take a dose of Ринопронт?

If a dose is missed when taking the drug on a regular schedule, the individual may be instructed to take it as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the individual may be instructed to skip the missed dose and resume the regular schedule. Regulatory guidance cautions against doubling the dose.


Q: Is there a maximum number of consecutive days that Ринопронт should be used?

Official documents state the product is intended for short, acute periods of symptomatic relief, and continued use should be based on a healthcare provider’s recommendation. This is to help ensure use is appropriate for the condition.


Q: Has any regulatory body issued specific warnings about Ринопронт?

Regulatory bodies have published specific reports regarding the risks of misuse or overdose associated with cough and cold preparations containing certain components of this drug, particularly when used in children younger than 2 years of age.


Q: Can Ринопронт affect the results of an allergy skin test?

Yes, the medicine contains an antihistamine component. Antihistamine compounds can interfere with the accuracy of an allergy skin test. Official medical guidance often requires patients to stop taking these compounds for a period before their testing appointment.


Q: Does Ринопронт help with a sore throat or only with nasal symptoms?

The general purpose of the medicine focuses on symptoms of rhinitis and the common cold, specifically nasal swelling and secretion. It is not indicated as a treatment for sore throat, although some of its anticholinergic effects may cause dry mouth or throat as a side effect.


Q: Are there generic versions of Ринопронт available?

Yes, for the active components used in this formulation, the FDA has approved generic versions of certain strengths and forms. A generic version must demonstrate that it is bioequivalent to the approved brand-name drug.


Q: What should I do if I experience a very rare or unexpected side effect?

Authoritative guidance suggests that any severe or concerning side effect warrants contacting a healthcare provider or seeking emergency medical assistance. Adverse effects can also be reported directly to regulatory bodies in their country.


Q: What evidence exists about the effectiveness of Ринопронт for typical cold symptoms?

Research has explored the variable of patient-reported symptoms in short-term studies, and meta-analyses have reported an association with symptom-related variables. However, overall findings across all published trials are described in official summaries as mixed.


Q: Is there a specific mechanism mentioned for how the second component, Carbinoxamine, works?

Yes, the mechanism for the Carbinoxamine component is described as acting as a competitive antagonist. This means it selectively binds to and blocks peripheral H1-histamine receptors, thereby preventing the body's natural histamine from activating the receptor.


Q: Does Ринопронт contain any substances that might be banned in sports?

The medicine contains Phenylephrine, which is classified as a stimulant. While some regulatory bodies may list it as an exception and not banned, athletes are officially reminded that they must check the status of all medications against the specific anti-doping list for their organized sport.


Q: Is it better to take Ринопронт in the morning or at night?

Official labeling defines the frequency of administration (e.g., typically every 12 hours) but does not define a 'best' time for everyone. Since the drug commonly causes sedation and sleepiness, the timing of the dose may be a factor to consider in light of the individual's daily activity level and sleep schedule.


Q: Is Ринопронт suitable for people with diabetes?

Official labeling states that use requires specific caution for patients who have diabetes mellitus. Patients with this condition should consult a healthcare provider before use.


Q: Do studies suggest any long-term effects associated with Ринопронт?

Official regulatory reviews indicate that long-term studies to determine the mutagenic and carcinogenic potentials of the Carbinoxamine component have not been performed to date. Overall evidence for use beyond six months remains limited.


Q: Is Ринопронт sold over-the-counter or does it require a prescription?

The product is generally classified as a prescription-strength medication. Authoritative sources identify the Carbinoxamine component as a prescription product, meaning the final product is available only with a doctor's prescription.


Q: Does Ринопронт interact with common painkillers like paracetamol or ibuprofen?

The drug combination is associated with a large number of potential drug interactions listed in regulatory sources. Due to the potential for interactions, patients are strongly cautioned that they must consult a healthcare provider or pharmacist to check for interactions with any other medications they are taking, including common painkillers.


Q: Is Ринопронт used for chronic sinus problems?

The medicine is intended for use over short, acute periods of symptomatic distress and for the relief of allergic rhinitis and cold symptoms. It is not indicated for the treatment or management of chronic sinus problems.

How should Ринопронт be stored and disposed of?

How to Store and Dispose of Ринопронт?

The storage of this medication must align strictly with the official regulatory requirements to ensure product stability and public safety.

Storage Requirement Official Condition
Temperature Store at a controlled room temperature between 15 C and 30 C (59 F to 86 F).
Protection Keep away from excess heat and moisture and maintain the product in a tightly closed, light-resistant container.
Child Safety Mandatory requirement to keep this medication out of the sight and reach of children.

For disposal, any unused or expired product must be handled in accordance with official guidelines. This often involves utilizing a local drug take-back program. The medicine should be secured in a safe, non-accessible location and should not be discarded in household wastewater unless specifically instructed by a regulatory body.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ринопронт found in:

A-Z Index: